XML 43 R30.htm IDEA: XBRL DOCUMENT v3.25.2
Common Stock and Stock-Based Compensation (Tables)
6 Months Ended 12 Months Ended
Jun. 30, 2025
Dec. 31, 2024
Common Stock and Stock-Based Compensation [Abstract]    
Schedule of Stock by Class

Common stock reserved for issuance at June 30, 2025 and December 31, 2024, was as follows:

 

   June 30,
2025
   December 31,
2024
 
Warrants outstanding for future issuance of Common stock   881,007    729,166 
Stock options and restricted stock units   438,384    353,908 
Stock options and restricted stock units available for future issuance   285,341    34,934 
Total shares of Common stock reserved   1,604,732    1,118,008 

Common stock reserved for issuance as of December 31, 2024 and 2023, is as follows:

 

    2024     2023  
Series A convertible preferred stock           78,699  
Series B convertible preferred stock           125,550  
Series C convertible preferred stock           74,925  
Series D convertible preferred stock           65,636  
Series E convertible preferred stock           57,616  
Warrants outstanding for future issuance of convertible preferred stock           4,343  
Warrants outstanding for future issuance of Common stock     729,166       66,858  
Stock options and restricted stock units     353,908       82,850  
Stock options and restricted stock units available for future issuance     34,934       33,523  
Total shares of common stock reserved     1,118,008       590,000  
Schedule of Option Award Activity For Performance Milestone-based Stock Options Granted

Option award activity for service-based stock options granted at June 30, 2025, was as follows:

 

    Number of
options
outstanding
    Weighted-
Average
Exercise Price
    Weighted-
Average
Remaining
Contractual
Life (Years)
    Aggregate
Intrinsic Value
(in thousand)
 
Balances at January 1, 2025     304,245     $ 31.60       9.5     $ 802  
Granted     70,859       5.90       -       -  
Exercised     -       -       -       -  
Expired     (3,076 )     87.40       -       -  
Forfeited     -       -               -                   -  
Balances at June 30, 2025     372,028     $ 26.16       9.2     $ -  
Vested and exercisable at June 30, 2025     179,314     $ 47.17       8.9     $ -  

Option award activity for performance milestone-based stock options granted at June 30, 2025, was as follows:

 

    Number of
options
outstanding
    Weighted-
Average
Exercise
Price
    Weighted-
Average
Remaining Contractual
Life
(Years)
    Aggregate
Intrinsic
Value
(in thousands)
 
Balances at January 1, 2025     5,106     $ 417.00       5.6     $ -  
Granted     -       -       -               -  
Exercised     -       -       -       -  
Expired     -       -       -       -  
Forfeited     -       -       -       -  
Balances at June 30, 2025     5,106     $ 417.00       5.1     $ -  
Vested and exercisable at June 30, 2025     1,702     $ 417.00       5.1     $ -  

Option award activity for service-based stock options granted as of December 31, 2024, was as follows:

 

   Number of
options
outstanding
   Weighted-
Average
Exercise Price
   Weighted-
Average
Remaining
Contractual
Life (Years)
   Aggregate
Intrinsic Value
(in thousand)
 
Balances as of January 1, 2023   48,506   $355.40    6.1   $2,561 
Granted   
     —
    
           —    
        —
 
Exercised   
    
        
 
Expired   (19,045)   319.00        
 
Forfeited   (7,668)   457.40        
 
Balances as of December 31, 2023   21,793   $352.00    4.8   $754 
Granted   282,528    6.80        
 
Exercised   
    
        
 
Expired   (76)   87.40        
 
Forfeited   
    
        
 
Balances as of December 31, 2024   304,245   $31.60    9.5   $802 
Options vested and exercisable at December 31, 2024   155,366   $54.20    9.1   $380 

A summary of the Company’s performance milestone-based stock options activity and related information is as follows:

 

   Number of
options
outstanding
   Weighted-
Average
Exercise Price
   Weighted-
Average
Remaining
Contractual
Life (Years)
   Aggregate
Intrinsic Value
(in thousands)
 
Balances as of January 1, 2023   5,254   $417.00    5.6   $463 
Granted   
    
        
 
Exercised   
    
          —
           —    
        —
 
Expired   
    
        
 
Forfeited   (148)   
        
 
Balances as of December 31, 2023   5,106   $417.00    6.6   $
 
Granted   
    
        
 
Exercised   
    
        
 
Expired   
    
        
 
Forfeited   
    
        
 
Balances as of December 31, 2024   5,106   $417.00    5.6   $
 
Vested and exercisable at December 31, 2024   1,702   $417.00    5.6   $
 
Schedule of Restricted Stock Units

A summary of the Company’s RSU activity and related information is as follows:

 

   Number of
RSUs
Outstanding
   Weighted-Average
Grant Date
Fair Value
Per Share
 
Balances at January 1, 2025   44,520   $193.80 
Granted   36,073    6.14 
Vested   (15,366)   86.31 
Forfeited   (3,977)   180.00 
Balances at June 30, 2025   61,250   $116.75 

A summary of the Company’s RSU activity and related information is as follows:

 

   Number of
RSUs
Outstanding
   Weighted-
Average
Grant Date
Fair Value
Per Share
 
Balances as of January 1, 2023   31,037   $442.20 
Granted   50,584    199.00 
Vested   
    
 
Forfeited   (25,730)   327.80 
Balances as of December 31, 2023   55,891   $272.80 
Granted   49,548    190.80 
Vested   (53,110)   272.80 
Forfeited   (7,809)   182.60 
Balances as of December 31, 2024   44,520   $193.80 
Schedule of Stock-Based Compensation Expense

The following table summarizes stock-based compensation expense recorded in each component of operating expenses in the Company’s interim condensed consolidated statements of operations and comprehensive loss (in thousands):

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2025   2024   2025   2024 
Research and development  $70   $-   $197   $- 
Sales and marketing   12    
-
    21    
-
 
General and administrative   1,481    97    3,476    195 
Total stock-based compensation expense  $1,563   $97   $3,694   $195 

The following table summarizes stock-based compensation expense recorded in each component of operating expenses in the Company’s consolidated statements of operations and comprehensive loss (in thousands):

 

   Year Ended December 31, 
   2024   2023 
Research and development  $3,000   $4 
Sales and marketing   1,446    1 
General and administrative   13,718    638 
Total stock-based compensation expense  $18,164   $643 
Schedule of Fair Value of Employee Service-Based Option Grants  

The following assumptions were used to calculate the fair value of employee service-based option grants made during the year ended December 31, 2024:

 

    2024 
Expected dividend yield(1)   
 
Risk-free interest rate(2)   4.17% - 4.20%
Expected volatility(3)   85.00%- 86.20%
Expected life (in years)(4)   0.76 - 6.50 
Fair value of common stock  $6.80 – 180.00 

 

(1) The Company has no history or expectation of paying cash dividends on its common stock and, thus, has assumed a zero-dividend rate.

 

(2) The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant.

 

(3) To determine the expected volatility used above, the Company used the average volatility of a peer group of representative public companies.

 

(4) The expected life or term of the options represents the period of time that options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).